CONMED (NASDAQ:CNMD) Lowered to Sell at StockNews.com

StockNews.com cut shares of CONMED (NASDAQ:CNMDGet Rating) from a hold rating to a sell rating in a research note published on Monday.

CONMED Stock Performance

Shares of CNMD opened at $97.57 on Monday. The stock has a 50 day simple moving average of $100.28. CONMED has a fifty-two week low of $87.24 and a fifty-two week high of $159.11. The stock has a market cap of $2.88 billion, a PE ratio of -24.64, a PEG ratio of 2.47 and a beta of 1.49. The company has a debt-to-equity ratio of 1.46, a current ratio of 2.87 and a quick ratio of 1.43.

CONMED (NASDAQ:CNMDGet Rating) last announced its quarterly earnings results on Wednesday, May 4th. The company reported $0.70 earnings per share for the quarter, topping the consensus estimate of $0.62 by $0.08. CONMED had a negative net margin of 10.93% and a positive return on equity of 13.94%. The firm had revenue of $242.33 million during the quarter, compared to analysts’ expectations of $235.55 million. Equities research analysts forecast that CONMED will post 3.42 EPS for the current year.

About CONMED

(Get Rating)

CONMED Corporation, a medical technology company, develops, manufactures, and sells surgical devices and related equipment for surgical procedures worldwide. It offers orthopedic surgery products, including TruShot with Y-Knot All-In-One Soft Tissue Fixation System, Y-knot All-Suture Anchors, and PopLok Knotless Suture Anchors, which provide unique clinical solutions to orthopedic surgeons for the repair of soft tissue injuries, as well as supporting products that enable surgeons to perform minimally invasive sports medicine surgeries.

Read More

Want More Great Investing Ideas?

Receive News & Ratings for CONMED Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CONMED and related companies with MarketBeat.com's FREE daily email newsletter.